Emerging therapies for rheumatoid arthritis

被引：14

作者：

Jacques, Peggy ^{[1
]}

Van den Bosch, Filip ^{[1
]}

机构：

[1] Ghent Univ Hosp, Dept Rheumatol, Ghent, Belgium

来源：

EXPERT OPINION ON EMERGING DRUGS | 2013年 / 18卷 / 02期

关键词：

biological therapy; cytokines; kinase inhibitors; rheumatoid arthritis; NECROSIS-FACTOR-ALPHA; INTERLEUKIN-1 RECEPTOR ANTAGONIST; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; INHIBITOR TOFACITINIB CP-690,550; MODIFYING ANTIRHEUMATIC DRUGS; ANTI-CD20; MONOCLONAL-ANTIBODY; CONTROLLED MULTICENTER TRIAL; PLACEBO-CONTROLLED TRIAL; PROOF-OF-CONCEPT; DOUBLE-BLIND;

D O I：

10.1517/14728214.2013.807339

中图分类号：

R9 [药学];

学科分类号：

100702 [药剂学];

摘要：

Introduction: With the introduction of biologic therapies, tremendous progress has been made in the treatment of rheumatoid arthritis (RA). However, up to 40% of patients do not respond to these treatments. Areas covered: Several new treatment strategies are discussed, with brief overview of currently performed clinical trials. The development of molecules targeting cytokines other than TNF is discussed, as well as chemokine-directed drugs. Finally, the area of small molecular inhibitors is explored. Expert opinion: Since RA is a life-long disease often evolving into disability, development of new treatment strategies remains crucial. Especially small molecules targeting JAK, Syk and PDE4 may provide novel therapeutic options.

引用

页码：231 / 244

页数：14

共 121 条

[1]

Aaltonen KJ, 2012, PLOS ONE, V7, DOI [10.1371/journal.pone.0030275, 10.1371/journal.pone.0043508]

[2]

Efficacy and safety of the human anti-IL-1beta monoclonal antibody canakinumab in rheumatoid arthritis: results of a 12-week, phase II, dose-finding study [J].

Alten, Rieke ;

Gomez-Reino, Juan ;

Durez, Patrick ;

Beaulieu, Andre ;

Sebba, Anthony ;

Krammer, Gerhard ;

Preiss, Ralph ;

Arulmani, Udayasankar ;

Widmer, Albert ;

Gitton, Xavier ;

Kellner, Herbert .

BMC MUSCULOSKELETAL DISORDERS, 2011, 12

[3]

[Anonymous], AM J HEALTH SYST PH

[4]

[Anonymous], ANN RHEUM DIS S3

[5]

Barnabe C, 2012, ANN RHEUM DIS

[6]

Targeting interleukin-15 in patients with rheumatoid arthritis - A proof-of-concept study [J].

Baslund, B ;

Tvede, N ;

Danneskiold-Samsoe, B ;

Larsson, P ;

Panayi, G ;

Petersen, J ;

Petersen, LJ ;

Beurskens, FJM ;

Schuurman, J ;

van de Winkel, JGJ ;

Parren, PWHI ;

Gracie, JA ;

Jongbloed, S ;

Liew, FY ;

McInnes, IB .

ARTHRITIS AND RHEUMATISM, 2005, 52 (09) :2686-2692

[7]

A missense single-nucleotide polymorphism in a gene encoding a protein tyrosine phosphatase (PTPN22) is associated with rheumatoid arthritis [J].

Begovich, AB ;

Carlton, VEH ;

Honigberg, LA ;

Schrodi, SJ ;

Chokkalingam, AP ;

Alexander, HC ;

Ardlie, KG ;

Huang, QQ ;

Smith, AM ;

Spoerke, JM ;

Conn, MT ;

Chang, M ;

Chang, SYP ;

Saiki, RK ;

Catanese, JJ ;

Leong, DU ;

Garcia, VE ;

McAllister, LB ;

Jeffery, DA ;

Lee, AT ;

Batliwalla, F ;

Remmers, E ;

Criswell, LA ;

Seldin, MF ;

Kastner, DL ;

Amos, CI ;

Sninsky, JJ ;

Gregersen, PK .

AMERICAN JOURNAL OF HUMAN GENETICS, 2004, 75 (02) :330-337

[8]

Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis [J].

Boers, M ;

Verhoeven, AC ;

Markusse, HM ;

vandeLaar, MAFJ ;

Westhovens, R ;

vanDenderen, JC ;

vanZeben, D ;

Dijkmans, BAC ;

Peeters, AJ ;

Jacobs, P ;

vandenBrink, HR ;

Schouten, HJA ;

vanderHeijde, DMFM ;

Boonen, A ;

vanderLinden, S .

LANCET, 1997, 350 (9074) :309-318

[9]

R406, an orally available spleen tyrosine kinase inhibitor blocks Fc receptor signaling and reduces immune complex-mediated inflammation [J].

Braselmann, Sylvia ;

Taylor, Vanessa ;

Zhao, Haoran ;

Wang, Su ;

Sylvain, Catherine ;

Baluom, Muhammad ;

Qu, Kunbin ;

Herlaar, Ellen ;

Lau, Angela ;

Young, Chi ;

Wong, Brian R. ;

Lovell, Scott ;

Sun, Thomas ;

Park, Gary ;

Argade, Ankush ;

Jurcevic, Stipo ;

Pine, Polly ;

Singh, Rajinder ;

Grossbard, Elliott B. ;

Payan, Donald G. ;

Masuda, Esteban S. .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2006, 319 (03) :998-1008

[10]

Modelling the cost effectiveness of TNF-α antagonists in the management of rheumatoid arthritis:: results from the British Society for Rheumatology Biologics Registry [J].

Brennan, A. ;

Bansback, N. ;

Nixon, R. ;

Madan, J. ;

Harrison, M. ;

Watson, K. ;

Symmons, D. .

RHEUMATOLOGY, 2007, 46 (08) :1345-1354

← 1 2 3 4 5 6 7 8 9 10 →